Research
Hormonal
Saturated long-chain fatty acids (LCFAs) promote insulin resistance and ectopic fat deposition via diacylglycerol (DAG) and ceramide accumulation, whereas medium-chain fatty acids (MCFAs) and polyunsaturated fats do not produce these detrimental effects.
Limit saturated long-chain fatty acids (found in animal fats and dairy) and prioritize unsaturated fats (olive oil, nuts, fish) and medium-chain fats. The source of fat significantly impacts metabolic health.
GoodSupportsHIGH confidence
High dietary and plasma levels of LCFA have been associated with obesity and insulin resistance, while MCFAs are not strongly associated with deterioration in metabolic health
Why this rating
Supported by animal models and human infusion studies showing causal links between specific fatty acids and insulin resistance.
Source
Macronutrient Determinants of Obesity, Insulin Resistance and Metabolic Health
Jibran A. Wali et al. · Biology · 2021
DOI 10.3390/biology10040336
narrative_reviewCited 60×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- High intake of fructose and high-glycemic carbohydrates promotes obesity and insulin resistance through de novo lipogenesis, ectopic lipid deposition, and inflammatory pathways, whereas high fiber intake improves metabolic health via short-chain fatty acid production and microbiome modulation.Good
- Dietary fiber intake improves metabolic health by increasing short-chain fatty acid (SCFA) production, which activates G-protein-coupled receptors (GPCRs) to enhance insulin sensitivity, energy expenditure, and gut microbiome diversity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →